AXSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Axsome Therapeutics Inc (AXSM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive growth potential and strong analyst support, the current technical indicators and financial performance suggest caution. The stock is in a downward trend, and there are no immediate catalysts or proprietary trading signals to justify a buy right now.
The MACD is negative and contracting (-2.298), indicating bearish momentum. RSI is at 20.713, which is in the neutral zone but trending towards oversold territory. The stock is trading near its S1 support level of 161.015, with no clear breakout above resistance levels. Moving averages are converging, showing indecision in the trend.
and positive sentiment around the potential approval of AXS-05 for Alzheimer's disease agitation. The company's revenue grew by 65.03% YoY in Q4 2025, and its gross margin improved to 92.89%.
The stock price has been declining (-1.60% regular market change, -0.53% post-market change). Net income dropped significantly (-61.88% YoY), and EPS also declined (-63.64% YoY). Technical indicators suggest bearish momentum, and options data reflects short-term bearish sentiment.
In Q4 2025, revenue increased significantly by 65.03% YoY to $195.99M, but net income dropped to -$28.56M (-61.88% YoY), and EPS fell to -0.56 (-63.64% YoY). Gross margin improved to 92.89%, indicating strong operational efficiency despite declining profitability.
Analysts are highly optimistic about AXSM, with multiple firms raising price targets (ranging from $202 to $251) and maintaining Buy or Outperform ratings. Analysts cite strong pipeline growth, operating leverage, and the potential approval of AXS-05 as key drivers for future growth.
